Conclusion
BALT lymphoma is a rare B-NHL with favorable prognosis. We here report on two patients with nonspecific symptoms: one showed as major symptom severe thrombocytopenia and the other dyspnea and dry cough, thereby suggesting an inflammatory focus in the lungs. There is no standard of care established yet. Both of our patients received an immunochemotherapy with rituximab/bendamustine. In previous studies and case reports, rituximab showed promising results and is commonly used as single agent treatment or in combination with chlorambucil or bendamustine. In our patients therapy with rituximab/bendamustine led to promising responses. Thus, we would recommend this immunochemotherapy as first-line therapy as in other MALT lymphomas, if an underlying chronic inflammatory disorder/trigger factor can be excluded. Nevertheless, more investigations and studies are necessary to unravel the underlying pathomechanism of BALT lymphomas, thus enabling to establish a standard of care.